Background: Epidemiological evidence suggests there are differences in gastroenteropancreatic neuroendocrine neoplasm (GEPNEN) among population groups. We aimed to contribute to the current evidence by evaluating the clinicopathological characteristics of GEPNEN in a multi-ethnic Asian group. Materials and Methods: This was a retrospective chart review of patients diagnosed with GEPNEN at a tertiary medical institution at Singhealth Outram Campus, Singapore, between 1995 and 2015. Results: Two hundred ninety-five patients were included in the evaluation, comprising Chinese (74.6%), Malay (4.4%), Indian (9.5%) and other (11.5%) ethnic backgrounds. The median age at diagnosis was 59 years; 52.5% were males. Distribution of disease stage at diagnosis was: localised (42.4%), regional (15.3%) and distant (38.0%). The three most common primary tumour sites were located in the pancreas (38.6%), rectum (19.7%) and stomach (9.5%), which varied significantly with ethnic background and age at diagnosis. Malay patients were younger (median 42 years) at diagnosis than Chinese (60 years). Patients with an appendiceal neuroendocrine neoplasm (NEN) (48 years) were younger compared to oesophageal NEN (66 years). Disease stage correlated with primary tumour site and grade (p < 0.001). Median overall survival (OS) for all GEPNEN was 10.2 years. Age at diagnosis, disease stage and grading were prognostic factors of OS in multivariable analyses. Conclusion: Our findings correspond with other studies that focus on GEPNEN incidences in Asian countries, with the pancreas, rectum and stomach being the most common primary tumour sites. Our findings suggest racial differences in primary tumour site and age at diagnosis. Further prospective population-based registries are required to understand these epidemiological differences.

1.
Yao
JC
,
Hassan
M
,
Phan
A
,
Dagohoy
C
,
Leary
C
,
Mares
JE
, et al.
One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
.
J Clin Oncol
.
2008
Jun
;
26
(
18
):
3063
72
.
[PubMed]
0732-183X
2.
Hauso
O
,
Gustafsson
BI
,
Kidd
M
,
Waldum
HL
,
Drozdov
I
,
Chan
AK
, et al.
Neuroendocrine tumor epidemiology: contrasting Norway and North America
.
Cancer
.
2008
Nov
;
113
(
10
):
2655
64
.
[PubMed]
0008-543X
3.
Ellis
L
,
Shale
MJ
,
Coleman
MP
.
Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971
.
Am J Gastroenterol
.
2010
Dec
;
105
(
12
):
2563
9
.
[PubMed]
0002-9270
4.
Lepage
C
,
Bouvier
AM
,
Phelip
JM
,
Hatem
C
,
Vernet
C
,
Faivre
J
.
Incidence and management of malignant digestive endocrine tumours in a well defined French population
.
Gut
.
2004
Apr
;
53
(
4
):
549
53
.
[PubMed]
0017-5749
5.
The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry study. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS
.
PLoS One
.
2013
Apr
;
8
(
4
):
e62487
.
[PubMed]
1932-6203
6.
Cho
MY
,
Kim
JM
,
Sohn
JH
,
Kim
MJ
,
Kim
KM
,
Kim
WH
, et al.;
Gastrointestinal Pathology Study Group of Korean Society of Pathologists
.
Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: multicenter Study
.
Cancer Res Treat
.
2012
Sep
;
44
(
3
):
157
65
.
[PubMed]
1598-2998
7.
Chan
DT
,
Luk
AO
,
So
WY
,
Kong
AP
,
Chow
FC
,
Ma
RC
, et al.
Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis
.
BMC Endocr Disord
.
2016
Feb
;
16
(
1
):
12
.
[PubMed]
1472-6823
8.
Fan
JH
,
Zhang
YQ
,
Shi
SS
,
Chen
YJ
,
Yuan
XH
,
Jiang
LM
, et al.
A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china
.
Oncotarget
.
2017
May
;
8
(
42
):
71699
708
.
[PubMed]
1949-2553
9.
Dasari
A
,
Shen
C
,
Halperin
D
,
Zhao
B
,
Zhou
S
,
Xu
Y
, et al.
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
.
JAMA Oncol
.
2017
Oct
;
3
(
10
):
1335
42
.
[PubMed]
2374-2437
10.
Population trend Singstat. Department of Statistics Singapore.
11.
Rindi
G
,
Arnold
R
,
Bosman
FT
, et al.
 Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon
2010
. p.13.
12.
Ohike
N
,
Adsay
NV
,
La Rosa
S
, et al.
 Mixed neuroendocrine-non-neuroendocrine neoplasms. In:
Lloyd
RV
,
Osamura
RY
,
Kloppel
G
,
Rosai
J
, editors
.
WHO Classification of Tumours of Endocrine Organs
. 4th ed.
Lyon
:
IARC Press
;
2017
. p.
238
.
13.
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from Natioal Cancer Registry of Spain (RGETNE). Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R
.
Ann Oncol
.
2010
Sep
;
21
(
9
):
1794
803
.
[PubMed]
0923-7534
14.
Niederle
MB
,
Hackl
M
,
Kaserer
K
,
Niederle
B
.
Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
.
Endocr Relat Cancer
.
2010
Oct
;
17
(
4
):
909
18
.
[PubMed]
1351-0088
15.
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). Jennifer A. Chan, Jason Edward Faris, Janet E. Murphy, Lawrence Scott Blaszkowsky, Eunice Lee Kwak, Nadine Jackson McCleary, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kimmie Ng, Andrew X. Zhu, Thomas Adam Abrams, Brian M. Wolpin, Sui Zhang, Amanda Reardon, Bridget Fitzpatrick, Matthew H. Kulke, and David P. Ryan. Journal of Clinical Oncology
2017
35:4_suppl, 228-228.
16.
Yao
JC
,
Oh
DY
,
Qian
J
,
Suk Park
Y
,
Fabian
H
,
Antonia
R
, et al.
Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study
.
Ann Oncol
.
2016
;
27
Supplement 7
:
vii15
6
. 0923-7534
17.
Gunavathy
M
,
Rohana
AG
,
Norlela
S
,
Nor Azmi
K
.
A ten-year retrospective analysis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Malaysia
.
Med J Malaysia
.
2014
Jun
;
69
(
3
):
133
7
.
[PubMed]
0300-5283
18.
Demographic Transition in Malaysia, Demographic Statistics Division, Malaysia
.
19.
Wang
YH
,
Lin
Y
,
Xue
L
,
Wang
JH
,
Chen
MH
,
Chen
J
.
Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China
.
BMC Endocr Disord
.
2012
Nov
;
12
(
1
):
30
.
[PubMed]
1472-6823
20.
Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrineneoplasms in China: a retrospective study. Zhang X, Ma L, Bao H, Zhang J, Wang Z, Gong P
.
BMC Endocr Disord
.
2014
Jul
;
14
:
54
.
[PubMed]
1472-6823
21.
Guo
LJ
,
Wang
CH
,
Tang
CW
.
Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution
.
Asia Pac J Clin Oncol
.
2016
Sep
;
12
(
3
):
284
8
.
[PubMed]
1743-7555
22.
Amarapurkar
DN
,
Juneja
MP
,
Patel
ND
,
Amarapurkar
AD
,
Amarapurkar
PD
.
A retrospective clinico-pathological analysis of neuroendocrine tumors of the gastrointestinal tract
.
Trop Gastroenterol
.
2010
Apr-Jun
;
31
(
2
):
101
4
.
[PubMed]
0250-636X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.